A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase IV Study to Evaluate the Efficacy and Safety of Tenelia in Patients Aged 65 and Older With Inadequately Controlled Type 2 Diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Teneligliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TEDDY
- Sponsors Handok Inc
- 06 Oct 2019 Planned End Date changed from 1 Jan 2020 to 4 Dec 2020.
- 06 Oct 2019 Planned primary completion date changed from 1 Nov 2019 to 4 Dec 2019.
- 06 Oct 2019 Status changed from recruiting to active, no longer recruiting.